SELLAS Life Sciences (SLS) Non Operating Income (2010 - 2026)
SELLAS Life Sciences (SLS) reported Non Operating Income of $845000.0 for Q1 2026, up 238.0% year-over-year from $250000.0 in Q1 2025, and up 41.54% on a QoQ basis from $597000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 15 years of Non Operating Income data on file, last reported at $845000.0 in Q1 2026.
- Quarterly Non Operating Income rose 238.0% year-over-year to $845000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 149.81% YoY) and the FY2025 annual result came in at $1.4 million, up 123.26% from the prior year.
- Non Operating Income advanced to $845000.0 in Q1 2026 per SLS's latest filing, from $597000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $845000.0 in Q1 2026 and bottomed at $41000.0 in Q4 2023.
- The 5-year median for Non Operating Income is $209500.0 (2022), against an average of $254687.5.
- The widest annual swing landed in 2023, when Non Operating Income plunged 87.38%; it then jumped 341.46% in 2024.
- Tracing SLS's Non Operating Income over 5 years: stood at $325000.0 in 2022, then sank by 87.38% to $41000.0 in 2023, then jumped by 341.46% to $181000.0 in 2024, then jumped by 229.83% to $597000.0 in 2025, then jumped by 41.54% to $845000.0 in 2026.
- Per Business Quant, the three latest SLS Non Operating Income figures stand at $845000.0 (Q1 2026), $597000.0 (Q4 2025), and $292000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 845,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 325,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Dec 31, 2019 | -7.50 Mn |
| Sep 30, 2019 | -4.20 Mn |
| Jun 30, 2019 | -3.13 Mn |
| Dec 31, 2018 | -14.86 Mn |
| Sep 30, 2018 | -290,000.00 |
| Jun 30, 2018 | -5.90 Mn |
| Dec 31, 2017 | -8.71 Mn |
| Sep 30, 2017 | -4.39 Mn |
| Jun 30, 2017 | -5.80 Mn |
| Mar 31, 2016 | -170,000.00 |
| Dec 31, 2015 | -4.44 Mn |
| Sep 30, 2015 | 307,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Mar 31, 2015 | -321,000.00 |
| Dec 31, 2014 | 15.68 Mn |
| Sep 30, 2014 | 597,000.00 |
| Jun 30, 2014 | -491,000.00 |
| Mar 31, 2014 | -165,000.00 |
| Dec 31, 2013 | -42.67 Mn |
| Sep 30, 2013 | -8.13 Mn |
| Jun 30, 2013 | -70,000.00 |
| Mar 31, 2013 | -5.44 Mn |
| Dec 31, 2012 | 11.55 Mn |
| Sep 30, 2012 | -733,000.00 |
| Jun 30, 2012 | 5.93 Mn |
| Mar 31, 2012 | -19.13 Mn |
| Dec 31, 2011 | 7.36 Mn |
| Sep 30, 2011 | -397,000.00 |
| Jun 30, 2011 | 685,000.00 |
| Mar 31, 2011 | 1.44 Mn |
| Dec 31, 2010 | 1.87 Mn |
| Sep 30, 2010 | -419,000.00 |
| Jun 30, 2010 | 2.61 Mn |